Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006153 · ClinicalTrials.gov registry record · Phase 1
Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00006153 is a Phase 1 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 45 participants.
The verdict
NCT00006153, a Phase 1 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to see if giving a vaccine (Remune) is effective in HIV-positive patients who are also taking anti-HIV therapy. Regular treatment of HIV-positive patients with anti-HIV drugs slows the multiplication of the HIV virus in the body. A vaccine called Remune works to stop the virus infection by "boosting" the body's immune cell defense against the HIV virus before the virus enters cells. It also blocks the virus from entering the cells. This study will see whether Remune will improve the immune cell natural defense in patients who are also taking anti-HIV drugs.
Interventions
- BIOLOGICAL HIV-1 Immunogen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006153
The ClinicalTrials.gov registry entry for NCT00006153 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HIV-1 Immunogen is the first listed.
NCT00006153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006153 about?
NCT00006153 is a clinical study titled "Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination". The purpose of this study is to see if giving a vaccine (Remune) is effective in HIV-positive patients who are also taking anti-HIV therapy. Regular treatment of HIV-positive patients with anti-HIV drugs slows the multiplication of the HIV virus in the body. A vaccine called Remune works to stop th...
What is the current status of trial NCT00006153?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 45 participants.
What interventions are being tested in trial NCT00006153?
The interventions under investigation include: HIV-1 Immunogen (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006153?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.